Protein tyrosine kinase receptor inhibitor diagnostic test - Biodesix

Drug Profile

Protein tyrosine kinase receptor inhibitor diagnostic test - Biodesix

Alternative Names: Erlotinib companion diagnostic; Ficlatuzumab companion diagnostic; VeriStrat test

Latest Information Update: 15 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biodesix
  • Developer AVEO Oncology; Biodesix; European Thoracic Oncology Platform
  • Class Diagnostic agents; Protein diagnostics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • No development reported Advanced breast cancer

Most Recent Events

  • 10 Jul 2017 Efficacy data from a retrospective analysis of the phase III LUX-lung 8 trial in Squamous cell carcinoma of the lung released by Biodesix
  • 01 Dec 2015 European Thoracic Oncology Platform completes the EMPHASIS-lung trial in Non-small cell lung cancer (Diagnosis) in United Kingdom, Switzerland, Spain, Netherlands, Israel, Ireland, Italy, Hungary, Greece, Denmark, Belgium, Austria, USA (unspecified route) (NCT01652469)
  • 24 Oct 2014 Veristrat® gets added into the National Comprehensive Cancer Network (NCCN) guidelines for Non-small cell lung cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top